Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, has entered into a research collaboration and license agreement with Pfizer to discover and develop Sec61 inhibitors.  

The collaboration aims to accelerate the discovery and advancement of novel small-molecule therapeutics leveraging Enodia’s proprietary platform, which enables selective Sec61 Translocon modulation, a novel approach to inhibit disease-driving proteins at the point of synthesis before pathological effects occur, while preserving essential physiological functions. Enodia has built a broad and well-characterised chemical space spanning multiple Sec61 inhibitor families, supported by extensive biological datasets, including proteomics, cryo-EM and tailored cell-line libraries that enable rational small-molecule design powered by machine learning. 

Yves Ribeill, Chief Executive Officer of Enodia Therapeutics, said: “We look forward to collaborating with Pfizer, combining their deep expertise and clinical resources with our approach for precisely targeting pathological proteins to bring forth potential new medicines.”   

Under the agreement, Enodia will conduct discovery activities to screen, optimise and develop Sec61 inhibitor candidates against multiple collaboration targets. After the collaboration term, Pfizer will be responsible for all clinical, manufacturing, regulatory and commercial activities.